Hyperthyroidism and other causes of thyrotoxicosis: Management guidelines of the american thyroid association and American association of clinical endocrinoloigists

Endocrine Practice

Volumn 17, Issue 3, 2011, Pages 456-520

  Bahn, Rebecca S ^a   Burch, Henry B ^b   Cooper, David S ^c   Garber, Jeffrey R ^d   Carol Greenlee, M ^e   Klein, Irwin ^f   Laurberg, Peter ^g   Ross McDougall, I ^h   Montori, Victor M ^a   Rivkees, Scott A ⁱ   Ross, Douglas S ^j   Sosa, Julie Ann ^k   Stan, Marius N ^a  

^a MAYO CLINIC   (United States)

^b WALTER REED ARMY MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^e Western Slope Endocrinology   (United States)

^f NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Department of Pediatrics   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

^k YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; RADIOACTIVE IODINE;

ADENOMA; ARTICLE; CLINICAL EXAMINATION; EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; EXPERIENCE; HUMAN; HYPERTHYROIDISM; INFORMATION RETRIEVAL; MEDICAL PRACTICE; MEDICAL SERVICE; MEDLINE; PANEL STUDY; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PREGNANCY; PUBLISHING; THYROTOXICOSIS; TOXIC GOITER; WESTERN HEMISPHERE;

EID: 79959628059     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP.17.3.456     Document Type: Article

References (358)

1. Singer PA, Cooper DS, Levy EG, et al (American Thyroid Association Standards of Care Committee).Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA. 1995;273:808-812.
2. Baskin HJ, Cobin RH, Duick DS, et al (American Association of Clinical Endocrinologists). American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract. 2002;8:457-469.
3. Atkins D, Best D, Briss PA, et al (GRADE Working Group). Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
4. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: Report from an american college of chest physicians task force. Chest. 2006;129:174-181. (Pubitemid 43265259)
5. Mechanick JI, Camacho PM, Cobin RH, et al (American Association of Clinical Endocrinologists). American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines-2010 update. Endocr Pract. 2010;16:270-283.
6. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: State-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666-673. (Pubitemid 351398536)
7. Berghout A, Wiersinga WM, Smits NJ, Touber JL. Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. Am J Med. 1990;89:602-608. (Pubitemid 20384317)
8. Gozu HI, Lublinghoff J, Bircan R, Paschke R. Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. Mol Cell Endocrinol. 2010;322:125-134.
9. Martin FI, Deam DR. Hyperthyroidism in elderly hospitalised patients. Clinical features and outcome. Med J Aust. 1996;164:200-203.
10. Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients. Medicine (Baltimore). 1974;53:161-181.
11. Tibaldi JM, Barzel US, Albin J, Surks M. Thyrotoxicosis in the very old. Am J Med. 1986;81:619-622. (Pubitemid 17178140)
12. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: Comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229:415-420.
13. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P. Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: A pattern of spontaneous evolution of the disease. J Clin Endocrinol Metab. 1988;67:656-662.
14. Williams I, Ankrett VO, Lazarus JH, Volpe R. Aetiology of hyperthyroidism in Canada and Wales. J Epidemiol Community Health. 1983;37:245-248. (Pubitemid 13013995)
15. Gerstein HC. How common is postpartum thyroiditis? A methodologic overview of the literature. Arch Intern Med. 1990;150:1397-1400. (Pubitemid 20215677)
16. Miller KK, Daniels GH. Association between lithium use and thyrotoxicosis caused by silent thyroiditis. Clin Endocrinol (Oxf). 2001;55:501-508. (Pubitemid 32955488)
17. Roti E, Minelli R, Giuberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996;101:482-487. (Pubitemid 126335968)
18. Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinology. 2010;6:34-41.
19. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ. Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. J Clin Endocrinol Metab. 2003;88: 2100-2105. (Pubitemid 36549883)
20. Klein I, Danzi S. Thyroid disease and the heart. Circulation. 2007;116:1725-1735. (Pubitemid 47537847)
21. Burch HB, Wartofsky L. Life-threatening hyperthyroidism: Thyroid storm. Endocrinol Metab Clin North Am. 1993; 22:263-277.
22. Hall P, Lundell G, Holm LE. Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Copenh). 1993;128:230-234. (Pubitemid 23100879)
23. Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J. A psychiatric and neuropsychological study of patients with untreated Graves' disease. Gen Hosp Psychiatry. 1988;10:49-55. (Pubitemid 18043784)
24. Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS. Graves' disease: An analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med. 1989; 87:558-561. (Pubitemid 19274761)
25. Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: A large cross-sectional study. J Clin Endocrinol Metab. 2010;95:2715-2726.
26. Ventrella S, Klein I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist. 1994;4:391-399. (Pubitemid 24308307)
27. European Heart Rhythm Association; Heart Rhythm Society, Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48:854-906. (Pubitemid 44175743)
28. Brennan MD, Coenen-Schimke JM, Bigelow ML, Nair KS. Changes in skeletal muscle protein metabolism and myosin heavy chain isoform messenger ribonucleic acid abundance after treatment of hyperthyroidism. J Clin Endocrinol Metab. 2006;91:4650-4656. (Pubitemid 44833452)
29. de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149:526-532. (Pubitemid 19092848)
30. Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990;70:453-460.
31. Rajatanavin R, Braverman LE. Euthyroid hyperthyroxinemia. J Endocrinol Invest. 1983;6:493-505. (Pubitemid 14198807)
32. Rajatanavin R, Liberman C, Lawrence GD, D'Arcangues CM, Young RA, Emerson CH. Euthyroid hyperthyroxinemia and thyroxine-binding prealbumin excess in islet cell carcinoma. J Clin Endocrinol Metab. 1985;61:17-21. (Pubitemid 15046188)
33. Socin HV, Chanson P, Delemer B, et al. The changing spectrum of TSH-secreting pituitary adenomas: Diagnosis and management in 43 patients. Eur J Endocrinol. 2003; 148:433-442. (Pubitemid 36527414)
34. Brucker-Davis F, Skarulis MC, Grace MB, et al. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study. Ann Intern Med. 1995;123:572-583.
35. Summaria V, Salvatori M, Rufini V, Mirk P, Garganese MC, Romani M. Diagnostic imaging in thyrotoxicosis. Rays. 1999;24:273-300. (Pubitemid 29426336)
36. Bogazzi F, Vitti P. Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? Nat Clin Pract Endocrinol Metab. 2008;4: 70-71. (Pubitemid 351156882)
37. Shigemasa C, Abe K, Taniguchi S, et al. Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves' disease despite similar serum total T4 levels. J Clin Endocrinol Metab. 1987;65:359-363. (Pubitemid 17103025)
38. Woolf PD. Transient painless thyroiditis with hyperthyroidism: A variant of lymphocytic thyroiditis? Endocr Rev. 1980;1:411-420.
39. Mariotti S, Martino E, Cupini C, et al. Low serum thyroglobulin as a clue to the diagnosis of hyperthyroidism factitia. N Engl J Med. 1982;307:410-412. (Pubitemid 12089296)
40. Bouillon R, Verresen L, Staels F, Bex M, De Vos P, De Roo M. The measurement of fecal thyroxine in the diagnosis of thyrotoxicosis factitia. Thyroid. 1993;3:101-103. (Pubitemid 23199731)
41. Costagliola S, Morgenthaler NG, Hoermann R, et al. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease. J Clin Endocrinol Metab. 1999;84:90-97. (Pubitemid 29036685)
42. Paunkovic J, Paunkovic N. Does autoantibody-negative Graves' disease exist? A second evaluation of the clinical diagnosis. Horm Met Res. 2006;38:53-56.
43. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: A comparison of two competitive binding assays. Clin Endocrinol (Oxf). 2001;55:381-390. (Pubitemid 32823048)
44. Klein I, Becker D, Levey GS. Treatment of hyperthyroid disease. Ann Int Med. 1994;121:281-288.
45. Wartofsky L, Glinoer D, Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States. Thyroid. 1991;1:129-135.
46. Abraham-Nordling M, Törring O, Hamberger B, et al. Graves' disease: A long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid. 2005;15:1279-1286. (Pubitemid 41821763)
47. Weingold AB. Appendicitis in pregnancy. Clin Obstet Gynecol. 1983;26:801-809. (Pubitemid 14219658)
48. Kuy SR, Roman SA, Desai R, Sosa JA. Outcomes following thyroid and parathyroid surgery in pregnant women. Arch Surg. 2009;144:399-406.
49. Träisk F, Tallstedt L, Abraham-Nordling M, et al. Thyroid-Associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94:3700-3707.
50. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med. 1983;75:353-359. (Pubitemid 13030880)
51. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: Systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334:514.
52. Delit C, Silver S, Yohalem SB, Segal RL. Thyrocardiac disease and its management with radioactive iodine I-131. JAMA. 1961;176:262-267.
53. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. J Clin Endocrinol Metab. 2001;86:3016-3021. (Pubitemid 32673459)
54. Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. J Clin Endocrinol Metab. 1999;84:4012-4016. (Pubitemid 30644188)
55. Klein I. Endocrine disorders and cardiovascular disease. In: Libby P, Bonow RO, Zipes DP, Mann DL, eds. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8th ed. Philadelphia, PA: Saunders/Elsevier, 2008: 2033-2047.
56. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338:712-718. (Pubitemid 28115089)
57. Turner JG, Brownlie BE, Rogers TG. Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. Lancet. 1976;1:614-615.
58. Bogazzi F, Bartalena L, Brogioni S, et al. Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. J Clin Endocrinol Metab. 1999;84:499-503. (Pubitemid 29075675)
59. Bogazzi F, Giovannetti C, Fessehatsion R, et al. Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: A cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab. 2010;95: 201-208.
60. Von Hofe SE, Dorfman SG, Carretta RF, Young RL. The increasing incidence of hypothyroidism within one year after radioiodine therapy for toxic diffuse goiter. J Nucl Med. 1978;19:180-184. (Pubitemid 8293726)
61. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves' hyperthyroidism: Standard vs. calculated 131 iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995;25:186-193.
62. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab. 2003;88:978-983. (Pubitemid 36337742)
63. Jarløv AE, Nygaard B, Hegedüs L, Hartling SG, Hansen JM. Observer variation in the clinical and laboratory evaluation of patients with thyroid dysfunction and goiter. Thyroid. 1998;8:393-398. (Pubitemid 28252420)
64. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: Results of a prospective, randomized, multicentre study. Eur J Clin Invest. 1996;26: 59-63. (Pubitemid 26046789)
65. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of Graves' hyperthyroidism with radioiodine: Results of a prospective randomized study. Thyroid. 1997;7:247-251. (Pubitemid 27190591)
66. Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab. 2000; 85:3058-3064.
67. Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves' disease. Thyroid. 2004;14: 525-530. (Pubitemid 39014591)
68. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280:347-355. (Pubitemid 28503219)
69. Sheline GE, Lindsay S, McCormack KR, Galante M. Thyroid nodules occurring late after treatment of thryotoxicosis with radioiodine. J Clin Endocrinol Metab. 1962; 22:8-18.
70. New England Congenital Hypothyroidism Collaborative. Elementary school performance of children with congenital hypothyroidism. J Pediatr. 1990;116: 27-32.
71. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294:71-80. (Pubitemid 41002841)
72. Goldman MB, Monson RR, Maloof F. Cancer mortality in women with thyroid disease. Cancer Res. 1990;50: 2283-2289. (Pubitemid 20134482)
73. Holm LE, Hall P, Wiklund K, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991;83:1072-1077.
74. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109: 1972-1979. (Pubitemid 46744190)
75. Ceccarelli C, Canale D, Battisti P, et al. Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf). 2006;65:446-452. (Pubitemid 44414267)
76. Fisher WD, Voorhess ML, Gardner LI. Congenital hypothyroidism in infant following maternal I-131 therapy with a review of hazards of environmental radioisotope contamination. J Pediatr. 1963;62:132-146.
77. Berg GE, Nyström EH, Jacobsson L, et al. Radioiodine treatment of hyperthyroidism in a pregnant women. J Nucl Med. 1998;39:357-361. (Pubitemid 28114532)
78. Woodings S. Radiation protection recommendations for I-131 thyrotoxicosis, thyroid cancer and phaeochromocytoma patients. Australas Phys Eng Sci Med. 2004;27: 118-128. (Pubitemid 39517320)
79. Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. Am J Med. 1995;99:173-179.
80. Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2022;87:1073-1077.
81. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352: 905-917. (Pubitemid 40300299)
82. Cooper DS. Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance. Ann Intern Med. 1985;102:328-331. (Pubitemid 15101861)
83. Cooper DS. Antithyroid drugs in the management of patients with Graves' disease: An evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88: 3474-3481. (Pubitemid 37034479)
84. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of drug therapy for Graves' hyperthyroidism. Eur J Endorinol. 2005;153:489-498. (Pubitemid 41556274)
85. Andersohn F, Konzen C, Garbe E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146:657-665. (Pubitemid 351650522)
86. Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D. Antithyroid drug-induced agranulocytosis: Clinical experience with ten patients treated at one institution and review of the literature. J Endocrinol Invest. 1994;17:29-36. (Pubitemid 24162540)
87. Kang AY, Baek YH, Sohn YJ, et al. Diffuse alveolar hemorrhage associated with antineutrophil cytoplasmic antibody levels in a pregnant woman taking propylthiouracil. Korean J Intern Med. 2006;21:240-243.
88. Noh JY, Yasuda S, Sato S, et al. Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. J Clin Endocrinol Metab. 2009;94:2806-2811.
89. Cin MO, Gursoy A, Morris Y, Aydintug OT, Kamel N, Gullu S. Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil. Int J Clin Pract. 2009;63:299-302.
90. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol. 2000;142:587.
91. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother. 2003;37:224-228. (Pubitemid 36172864)
92. Bahn RS, Burch HS, Cooper DS, et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: Report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid. 2009;19:673-674.
93. U.S. Food and Drug Administration. Information for Healthcare Professionals - Propylthiouracil-Induced Liver Failure. June 4, 2009. Available at: Http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformation forPatientsandProviders/DrugSafetyInformationfor HeathcareProfessionals/ ucm162701.htm. Accessed March 15, 2011.
94. Vilchez FJ, Toores I, Garcia-Valero A, Lopez-Tinoco C, de Los Santos A, Aguilar-Diosdado M. Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole. Ann Pharmacother. 2006;40:2059-2063. (Pubitemid 44747480)
95. Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract. 2002;8:222-224. (Pubitemid 34555516)
96. Shivakumar SK, Dwarakanath S, Swaroop G, Venkataramana NK. Aplasia cutis congenita of the scalp: Therapeutic modalities. Neurol India. 2006;54:312-313. (Pubitemid 44341777)
97. Wolf D, Foulds N, Daya H. Antenatal carbimazole and choanal atresia: A new embryopathy. Arch Otolaryngol Head Neck Surg. 2006;132:1009-1011. (Pubitemid 44423385)
98. Clark SM, Saade GR, Snodgrass WR, Hankins GD. Pharmacokinetics and pharmacotherapy of thionamides in pregnancy. Ther Drug Monit. 2006;28:477-483. (Pubitemid 44181481)
99. Ross DS. Patient information: Antithyroid drugs. UpToDate. Available at: Http://www.uptodate.com/patients/content/topic.do?topicKey=~K7dgOAIby0pAB7& source=see-link. Accessed March 16, 2011.
100. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med. 1990;150:621-624. (Pubitemid 20122017)
101. Ahmed K, Rao S, Simha V. ANCA-positive vasculitis in a patient with Graves' disease: Cross-reaction between Propylthiouracil and Methimazole. Endocr Pract. 2010;9:1-11.
102. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. Ann Intern Med. 1993;118:424-428.
103. Benyounes M, Sempoux C, Daumerie C, Rahier J, Geubel AP. Propylthiouracyl-induced severe liver toxicity: An indication for alanine aminotransferase monitoring? World J Gastroenterol. 2006;12:6232-6234. (Pubitemid 44688180)
104. Kim HJ, Kim BH, Han YS, et al. The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: A single-center retrospective study. Am J Gastroenterol. 2001;96:165-169.
105. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2007;92:2157-2162. (Pubitemid 46997115)
106. Weiss M, Hassin D, Bank H. Propylthiouracil-induced hepatic damage. Arch Intern Med. 1980;140:1184-1185. (Pubitemid 10048813)
107. Waseem M, Seshadri KG, Kabadi UM. Successful outcome with methimazole and lithium combination therapy for propylthiouracil-induced hepatotoxicity. Endocr Pract. 1998;4:197-200.
108. Mazza E, Carlini M, Flecchia D, et al. Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: A retrospective study. J Endocrinol Invest. 2008;31:866-872.
109. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR. Does smoking increase relapse rates in Graves' disease? J Endocrinol Invest. 2002;25:152-157. (Pubitemid 34232615)
110. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for Graves' hyperthyroidism. J Clin Endocrinol Metab. 2000;85:1038-1042. (Pubitemid 32269346)
111. Nedrebo BG, Holm PI, Uhlving S, et al. Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol. 2002;147:583-589. (Pubitemid 35414555)
112. Orunesu E, Bagnasco M, Salmaso C, et al. Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal. Eur J Clin Invest. 2004;34:210-217. (Pubitemid 38406636)
113. Bolanos F, Gonzalez-Ortiz M, Duron H, Sanchez C. Remission of Graves' hyperthyroidism treated with methimazole. Rev Invest Clin. 2002;54:307-310. (Pubitemid 35282687)
114. Orgiazzi J, Madec AM. Reduction of the risk of relapse after withdrawal of medical therapy for Graves' disease. Thyroid. 2002;12:849-853. (Pubitemid 35332988)
115. Glinoer D, de Nayer P, Bex M (Belgian Collaborative Study Group on Graves' Disease). Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: A double-blind prospective randomized study. Eur J Endocrinol. 2001;144:475-483. (Pubitemid 32487523)
116. Takasu N, Yamashiro K, Komiya I, Ochi Y, Sato Y, Nagata A. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment. Thyroid. 2000;10:891-896.
117. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J. Goitre size and outcome of medical treatment of Graves' disease. Acta Endocrinol (Copenh). 1986;111:39-43. (Pubitemid 16187044)
118. Erbil Y, Ozluk Y, Giris M, et al. Effect of Lugol solution on thyroid gland, blood flow and micovessel density in patients with Graves' disease. J Clin Endocrinol Metab. 2007;92:2182-2189. (Pubitemid 46997119)
119. Ansaldo GL, Pretolesi F, Varaldo E, et al. Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter. J Am Coll Surg. 2000;191:607-612. (Pubitemid 32004985)
120. Baeza A, Aguayo J, Barria M, Pineda G. Rapid preoperative preparation in hyperthyroidism. Clin Endocrinol (Oxf). 1991;35:439-442.
121. Palit TK, Miller CC 3rd, Miltenburg DM. The efficacy of thyroidectomy for Graves' disease: A meta-analysis. J Surg Res. 2000;90:161-165. (Pubitemid 30314455)
122. Sosa JA, Mehta PJ, Wang TS, Boudourakis L, Roman SA. A population based study of outcomes from thyroidectomy in aging Americans: At what cost? J Am Coll Surg. 2008;206:1097-1105.
123. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320-330. (Pubitemid 30191695)
124. Röher HD, Goretzki PE, Hellmann P, Witte J. Complications in thyroid surgery. Incidence and therapy [in German]. Chirurg. 1999;70:999-1010.
125. Abbas G, Dubner S, Heller KS. Re-operation for bleeding after thyroidectomy and parathyroidectomy. Head Neck. 2001;23:544-546. (Pubitemid 32565527)
126. Jenkins K, Baker AB. Consent and anaesthetic risk. Anaesthesia. 2003;58:962-984. (Pubitemid 37254177)
127. Husein M, Hier MP, Al-Abdulhadi K, Black M. Predicting calcium status post-thyroidectomy with early calcium levels. Otolaryngol Head Neck Surg. 2002;127: 289-293. (Pubitemid 36541455)
128. Sywak MS, Palazzo FF, Yeh M, et al. Parathyroid hormone assay predicts hypocalcaemia after total thyroidectomy. ANZ J Surg. 2007;77:667-670. (Pubitemid 47063356)
129. Wiseman JE, Mossanen M, Ituarte PH, Bath JM, Yeh MW. An algorithm informed by the parathyroid hormone level reduces hypocalcemic complications of thyroidectomy. World J Surg. 2010;34:532-537.
130. Sabour S, Manders E, Steward DL. The role of rapid PACU parathyroid hormone in reducing post-thyroidectomy hypocalcemia. Otolaryngol Head Neck Surg. 2009; 141:727-729.
131. Jumaily JS, Noordzij JP, Dukas AG, et al. Prediction of hypocalcemia after using 1- to 6-hour postoperative parathyroid hormone and calcium levels: An analysis of pooled individual patient data from 3 observational studies. Head Neck. 2010;32:427-434.
132. McLeod IK, Arciero C, Noordzij JP, et al. The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. Thyroid. 2006;16:259-265.
133. Kaplan EL, Angelos P.Surgery of the Thyroid Gland. Thyroid Disease Manager. Available at: Www.thyroidmanager.org/Chapter21/21-frame.htm. Accessed February 22, 2011.
134. Noordzij JP, Lee SL, Bernet VJ, et al. Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: An analysis of pooled individual patient data from nine observational studies. J Am Coll Surg. 2007;205: 748-754. (Pubitemid 350116625)
135. Cote V, Sands N, Hier MP, et al. Cost savings associated with post-thyroidectomy parathyroid hormone levels. Otolaryngol Head Neck Surg. 2008;138:204-208. (Pubitemid 351172503)
136. Bellantone R, Lombardi CP, Raffaelli M, et al. Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy? Surgery. 2002;132:1109-1113. (Pubitemid 36026962)
137. Wilson RB, Erskine C, Crowe PJ. Hypomagnesemia and hypocalcemia after thyroidectomy: Prospective study. World J Surg. 2000;24:722-726. (Pubitemid 30331849)
138. Roh JL, Park CI. Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. Am J Surg. 2006;192:675-678. (Pubitemid 44634327)
139. Stocker DJ, Burch HB. Thyroid cancer yield in patients with Graves' disease. Minerva Endocrinol. 2003;28: 205-212.
140. Kikuchi S, Noguchi S, Yamashita H, Uchino S, Kawamoto H. Prognosis of small thyroid cancer in patients with Graves' disease. Br J Surg. 2006;93:434-439.
141. Cappelli C, Pirola I, De Martino E, et al. The role of imaging in Graves' disease: A cost-effectiveness analysis. Eur J Radiol. 2007;65:99-103.
142. Cakir M, Arici C, Alakus H, Altunbas H, Balci MK, Karayalcin U. Incidental thyroid carcinoma in thyrotoxic patients treated by surgery. Horm Res. 2007;67:96-99. (Pubitemid 46333778)
143. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214.
144. Gharib H, Papini E, Paschke R, et al (AACE/AME/ETA Task Force on Thyroid Nodules). American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical Guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2010; 16:468-475.
145. Nayak B, Burman K. Thyrotoxicosis and thyroid storm. Endocrinol Metab Clin North Am. 2006;35:663-686. (Pubitemid 44802966)
146. Roti E, Robuschi G, Gardini E, et al. Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. Clin Endocrinol (Oxf). 1988;28:305-314. (Pubitemid 18079400)
147. Erickson D, Gharib H, Li H, van Heerden JA. Treatment of patients with toxic multinodular goiter. Thyroid. 1998;8:277-282. (Pubitemid 28198719)
148. Kang AS, Grant CS, Thompson GB, van Heerden JA. Current treatment of nodular goiter with hyperthyroidism (Plummer's disease): Surgery versus radioiodine. Surgery. 2002;132:916-923. (Pubitemid 36026936)
149. Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159:1364-1368. (Pubitemid 29293600)
150. Holm LE, Lundell G, Israelsson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med. 1982;23:103-107. (Pubitemid 12166906)
151. Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: Dissecting an important decision. A cost-effectiveness analysis. Thyroid. 2004; 14:933-945. (Pubitemid 39612912)
152. Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf). 1999;50:197-202. (Pubitemid 29100006)
153. Vaiman M, Nagibin A, Hagag P, Kessler A, Gavriel H. Hypothyroidism following partial thyroidectomy. Otolaryngol Head Neck Surg. 2008;138:98-100. (Pubitemid 350299637)
154. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: A 20 years' retrospective study. Clin Endocrinol (Oxf). 2005;62:331-335. (Pubitemid 40380414)
155. Goldstein R, Hart IR. Follow-up of solitary autonomous thyroid nodules treated with 131I. N Engl J Med. 1983;309:1473-1476. (Pubitemid 14211570)
156. Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML. Evidence-based management of toxic multinodular goiter (Plummer's Disease). World J of Surg. 2008;32:1278-1284.
157. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 as an alternative to surgery in patients with a very large goiter; effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999;84:3636-3641. (Pubitemid 30645217)
158. Wahl RA, Rimpl I, Saalabian S, Schabram J. Differentiated operative therapy of thyroid autonomy (Plummer's disease). Exp Clin Endocrinol Diabetes. 1998; 106:S78-S84. (Pubitemid 28537595)
159. van Soestbergen MJ, van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: A comparison with Graves' disease. J Endocrinol Invest. 1992;15:797-800. (Pubitemid 23060029)
160. Nygaard B, Faber J, Veje A, Hegedüs L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by I131 therapy. Thyroid. 1999;9: 477-481. (Pubitemid 29244925)
161. Hall P, Berg G, Bjelkengren G, et al. Cancer mortality after iodine-131 therapy for hyperthyroidism. Int J Cancer. 1992;50:886-890.
162. Becker DV, Hurley JR. Complications of radioiodine treatment of hyperthyroidism. Semin Nucl Med. 1971;1: 442-460.
163. Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. 2008;14:832-839.
164. Koornstra JJ, Kerstens MN, Hoving J, et al. Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. Neth J Med. 1999;55:215-221. (Pubitemid 29502440)
165. Cerci C, Cerci SS, Eroglu E, et al. Thyroid cancer in toxic and non-toxic multinodular goiter. J Postgrad Med. 2007;53:157-160. (Pubitemid 47281968)
166. Ferrari C, Reschini E, Paracchi A. Treatment of the autonomous thyroid nodule: A review. Eur J Endocrinol. 1996;135:383-390. (Pubitemid 26364936)
167. Albino CC, Graf H, Sampaio AP, Vigário A, Paz-Filho GJ. Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs. 2008;17:1781-1786.
168. Magner J. Problems associated with the use of thyrogen in patients with a thyroid gland. N Engl J Med. 2008;359: 1738-1739.
169. Zakavi SR, Mousavi Z, Davachi B. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun. 2009;30:169-175.
170. Dobyns BM. Prevention and management of hyperthyroid storm. World J Surg. 1978;2:293-306. (Pubitemid 9023773)
171. Hamilton WF, Forrest AL, Gunn A, Peden NR, Feely J. Beta-adrenoceptor blockade and anaesthesia for thyroidectomy. Anaesthesia. 1984;39:335-342. (Pubitemid 15118363)
172. F́leisher LA. Risk of anesthesia. In: Miller RD, ed. Anesthesia. 5th ed. Philadelphia, PA: Churchill Livingstone; 2000: 795-823.
173. Spanknebel K, Chabot JA, DiGiorgi M, et al. Thyroidectomy using local anesthesia: A report of 1,025 cases over 16 years. J Am Coll Surg. 2005;201:375-385. (Pubitemid 41206775)
174. Siegel RD, Lee SL. Toxic nodular goiter: Toxic adenoma and toxic multinodular goiter. Endocrinol Metab Clin N Am. 1998;27:151-168. (Pubitemid 28144960)
175. Reeve TS, Delbridge L, Cohen A, Crummer P. Total thyroidectomy. The preferred option for multinodular goiter. Ann Surg. 1987;203:782-786.
176. Mishra A, Agarwal A, Agarwal G, Mishra SK. Total thyroidectomy for benign thyroid disorders in an endemic region. World J Surg. 2001;25:307-310. (Pubitemid 32410371)
177. Pappalardo G, Guadalaxara A, Frattaroli FM, Illomei G, Falaschi P. Total compared with subtotal thyroidectomy in benign nodular disease: Personal series and review of published reports. Eur J Surg. 1998;164:501-506. (Pubitemid 28328259)
178. Hisham AN, Azlina AF, Aina EN, Sarojah A. Total thyroidectomy: The procedure of choice for multinodular goitre. Eur J Surg. 2001;167:403-405. (Pubitemid 32607813)
179. Al-Suliman NN, Ryttov NF, Qvist N, Blichert-Toft M, Graversen HP. Experience in a specialist thyroid surgery unit; a demographic study, surgical complications, and outcome. Eur J Surg. 1997;163:13-20. (Pubitemid 27062346)
180. Thomusch O, Machens A, Sekulla C, et al. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: Prospective multicenter study in Germany. World J Surg. 2000;24:1335-1341.
181. Bliss R, Patel N, Guinea A, Reeve TS, Delbridge L. Age is no contraindication to thyroid surgery. Age Ageing. 1999;28:363-366. (Pubitemid 29346831)
182. Sosa JA, Mehta PJ, Wang TS, Yeo HL, Roman SA. Racial disparities in clinical and economic outcomes from thyroidectomy. Ann Surg. 2007;246:1083-1091. (Pubitemid 350179203)
183. Takáts KI, Szabolcs I, Földes J, et al. The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goiter compared to radioiodine therapy with different doses. Exp Clin Endocrinol Diabetes. 1999;107: 70-74. (Pubitemid 29082071)
184. Tarantino L, Francica G, Sordelli I, et al. Percutaneous ethanol injection of hyperfunctioning thyroid nodules: Long-term follow-up in 125 patients. AJR Am J Roentgenol. 2008;190:800-808. (Pubitemid 351304528)
185. Monzani F, Caraccio N, Goletti O, et al. Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: A study of 117 patients. Clin Endocrinol (Oxf). 1997;46:9-15. (Pubitemid 27072840)
186. Zingrillo M, Modoni S, Conte M, Frusciante V, Trischitta V. Percutaneous ethanol injection plus radioiodine versus radioiodine along in the treatment of large toxic thyroid nodules. J Nucl Med. 2003;44:207-210.
187. Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev. 2008;16:CD006294.
188. Rivkees SA, Sklar C, Freemark M. Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998;83:3767-3776.
189. Levy WJ, Schumacher OP, Gupta M. Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleve Clin J Med. 1988;55:373-382.
190. Lee JA, Grumbach MM, Clark OH. The optimal treatment for pediatric Graves' disease is surgery. J Clin Endocrinol Metab. 2007;92:801-803.
191. Freitas JE, Swanson DP, Gross MD, Sisson JC. Iodine-131: Optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med. 1979;20:847-850. (Pubitemid 9220379)
192. Boice JD Jr. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA. 2006;295:1060-1062.
193. Boice JD Jr. Radiation-induced thyroid cancer-what's new? J Natl Cancer Inst. 2005;97:703-705.
194. Sosa JA, Tuggle CT, Wang TS, et al. Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab. 2008;93:3058-3065.
195. Tuggle CT, Roman SA, Wang TS, et al. Pediatric endocrine surgery: Who is operating on our children? Surgery. 2008;144:869-877.
196. Nicholas WC, Fischer RG, Stevenson RA, Bass JD. Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. South Med J. 1995;88:973-976.
197. Sato H, Harada S, Yokoya S, et al. Treatment for childhood-onset Graves' disease in Japan: Results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. Thyroid. 2007;17:67-72. (Pubitemid 46214728)
198. Cassio A, Corrias A, Gualandi S, et al. Influence of gender and pubertal stage at diagnosis on growth outcome in childhood thyrotoxicosis: Results of a collaborative study. Clin Endocrinol (Oxf). 2006;64:53-57.
199. Dötsch J, Rascher W, Dorr HG. Graves disease in childhood: A review of the options for diagnosis and treatment. Paediatr Drugs. 2003;5:95-102. (Pubitemid 36197590)
200. Dötsch J, Siebler T, Hauffa BP, et al. Diagnosis and management of juvenile hyperthyroidism in Germany: A retrospective multicenter study. J Pediatr Endocrinol Metab. 2000;13:879-885.
201. Mussa GC, Corrias A, Silvestro L, et al. Factors at onset predictive of lasting remission in pediatric patients with Graves' disease followed for at least three years. J Pediatr Endocrinol Metab. 1999;12:537-541. (Pubitemid 29334733)
202. Perrild H, Grüters-Kieslich A, Feldt-Rasmussen U, et al. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994;131:467-473. (Pubitemid 24349186)
203. Slyper AH, Wyatt D, Boudreau C. Effective methimazole dose for childhood Grave's disease and use of free triiodothyronine combined with concurrent thyroid-stimulating hormone level to identify mild hyperthyroidism and delayed pituitary recovery. J Pediatr Endocrinol Metab. 2005;18:597-602. (Pubitemid 40916489)
204. Smith J, Brown RS. Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. Thyroid. 2007;17:1103-1107. (Pubitemid 350207756)
205. Abraham P, Avenell A, Watson WA, Park CM, Bevan JS. Antithyroid drug regimen for treating Graves' hyperthyroidism. Cochrane Database Syst Rev. 2005;18: CD003420.
206. Razvi S, Vaidya B, Perros P, Pearce SH. What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. Eur J Endocrinol. 2006;154:783-786. (Pubitemid 43997715)
207. Cooper DS, Goldminz D, Levin AA, et al. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983;98:26-29. (Pubitemid 13217959)
208. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360: 1574-1575.
209. Rivkees SA, Mattison DR. Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use. Intl J Pediatr Endocrinol. 2009; 132041.
210. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Hepatic Toxicity Following Treatment for Pediatric Graves' Disease Meeting on October 28, 2008. Available at: Http://bpca.nichd.nih.gov/ collaborativeefforts/upload/Hepatic-Toxicity-10-28-08-final-final-01-09-09.pdf. Accessed March 16, 2011.
211. Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers in patients with reactive airway disease: A meta-analysis. Ann Intern Med. 2002;137:715-725. (Pubitemid 35265315)
212. Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of graves' disease in children. Int J Pediatr Endocrinol. 2010;2010:176970.
213. Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab. 1985;60: 1019-1024. (Pubitemid 15085138)
214. Kaguelidou F, Alberti C, Castanet M, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab. 2008;93:3817-3826.
215. Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis: How has granulocyte colony-stimulating factor changed therapy? Thyroid. 2005;15:292-297. (Pubitemid 40418698)
216. Lazar L, Kalter-Leibovici O, Pertzelan A, Weintrob N, Josefsberg Z, Phillip M. Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. J Clin Endocrinol Metab. 2000;85:3678-3682.
217. Weetman AP. Graves' hyperthyroidism: How long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab. 2006;2:2-3.
218. Glaser NS, Styne DM (Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group). Predicting the likelihood of remission in children with Graves' disease: A prospective, multicenter study. Pediatrics. 2008;121:e481-e488.
219. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW. Autoimmune hyperthyroidism in prepubertal children and adolescents: Comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid. 1997;7:755-760. (Pubitemid 28086207)
220. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: Twenty-five percent remission every two years. J Clin Endocrinol Metab. 1987;64:1241-1245. (Pubitemid 17074785)
221. Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab. 1997;82:1719-1726. (Pubitemid 127495174)
222. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: A 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69-75. (Pubitemid 351211042)
223. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA. Thyroid storm in a child following radioactive iodine (RAI) therapy: A consequence of RAI versus withdrawal of antithyroid medication. J Clin Endocrinol Metab. 2001;86:1865-1867. (Pubitemid 32472886)
224. Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111:745-749. (Pubitemid 36402897)
225. Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L. Resumption of methimazole after 131I therapy of hyperthyroid diseases: Effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol. 2003;149:485-492. (Pubitemid 38063062)
226. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr. 2002;141:99-103. (Pubitemid 34774958)
227. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: A report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. J Clin Endocrinol Metab. 1974; 38:976-998.
228. Boice JD Jr. Radiation and thyroid cancer: What more can be learned? ACTA Oncol. 1998;37:321-324.
229. Dolphin GW. The risk of thyroid cancers following irradiation. Health Phys. 1968;15:219-228.
230. Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab. 2007;92:797-800.
231. Ueda D. Normal volume of the thyroid gland in children. J Clin Ultrasound. 1990;18:455-462. (Pubitemid 20194473)
232. Kalinyak JE, McDougall IR. How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism? J Clin Endocrinol Metab. 2003;88:975-977. (Pubitemid 36337741)
233. Rivkees SA. The treatment of Graves' disease in children. J Pediatr Endocrinol Metab. 2006;19:1095-1111. (Pubitemid 44613765)
234. Rivkees SA. Graves' disease therapy in children: Truth and inevitable consequences. J Pediatr Endocrinol Metab. 2007;20:953-955. (Pubitemid 350031270)
235. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: A pooled analysis of seven studies. Radiat Res. 1995;141:259-277.
236. Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): A nested case-control study. Lancet. 2005;365:2014-2023. (Pubitemid 40805009)
237. Davis S, Kopecky KJ, Hamilton TE, Onstad L (Hanford Thyroid Disease Study Team). Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. JAMA. 2004;292:2600-2613. (Pubitemid 39577516)
238. Dickman PW, Holm LE, Lundell G, Boice JD Jr, Hall P. Thyroid cancer risk after thyroid examination with 131I: A population-based cohort study in Sweden. Int J Cancer. 2003;106:580-587. (Pubitemid 36966217)
239. Shore RE. Issues and epidemiological evidence regarding radiation-induced thyroid cancer. Radiat Res. 1992;131: 98-111.
240. Read CH, Jr., Tansey MJ, Menda Y. A 36 year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab. 2004;89:4229-4233. (Pubitemid 39244416)
241. Toohey RE, Stabin MG, Watson EE. The AAPM/RSNA physics tutorial for residents: Internal radiation dosimetry: Principles and applications. Radiographics. 2000;20: 533-546.
242. Committee to Assess Health Risks From Exposure to Low Levels of Ionizing Radiation, Board on Radiation Effects, Division on Earth and Life Studies, National Research Council of the National Academies. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII - Phase 2. Washington DC: National Academies Press, 2006.
243. Miccoli P, Vitti P, Rago T, et al. Surgical treatment of Graves' disease: Subtotal or total thyroidectomy? Surgery. 1996;120:1020-1024; discussion 1024-1025.
244. Sherman J, Thompson GB, Lteif A, et al. Surgical management of Graves disease in childhood and adolescence: An institutional experience. Surgery. 2006;140:1056-1061; discussion 1061-1062.
245. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87:489-499. (Pubitemid 34158210)
246. Diez JJ. Hyperthyroidism in patients older than 55 years: An analysis of the etiology and management. Gerontology. 2003;49:316-323. (Pubitemid 37034368)
247. Abraham-Nordling M, Törring O, Lantz M, et al. Incidence of hyperthyroidism in Stockholm, Sweden, 2003-2005. Eur J Endocrinol. 2008;158:823-827. (Pubitemid 351837371)
248. Lewis GF, Alessi CA, Imperial JG, Refetoff S. Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. J Clin Endocrinol Metab. 1991;73:843-849. (Pubitemid 21921947)
249. Mariotti S, Barbesino G, Caturegli P, et al. Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab. 1993;77:1130-1134. (Pubitemid 23345457)
250. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC. Prevalence and follow-up of abnormal thyrotrophin (TSH) concentrations in the elderly in the United Kingdom. Clin Endocrinol (Oxf). 1991;34:77-83.
251. Bjørndal MM, Sandmo Wilhelmsen K, Lu T, Jorde R. Prevalence and causes of undiagnosed hyperthyroidism in an adult healthy population. The Tromsø study. J Endocrinol Invest. 2008;31:856-860.
252. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI. Serum thyrotropin measurements in the community: Five-year follow-up in a large network of primary care physicians. Arch Intern Med. 2007;167: 1533-1538. (Pubitemid 47124184)
253. Woeber KA. Observations concerning the natural history of subclinical hyperthyroidism. Thyroid. 2005;15:687-691. (Pubitemid 41117521)
254. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252. (Pubitemid 24333188)
255. Cappola AR, Fried LP, Arnold AM, et al. Thyroid status, cardiovascular risk, and mortality in older adults. JAMA. 2006;295:1033-1041.
256. Sgarbi JA, Villaca F, Garbeline B, Villar H E, Romaldini JH. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab. 2003;88:1672-1677. (Pubitemid 36623386)
257. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001;145: 391-396. (Pubitemid 32927063)
258. Biondi B, Palmieri EA, Fazio S, et al. Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. J Clin Endocrinol Metab. 2000;85:4701-4705. (Pubitemid 32157655)
259. Bauer DC, Ettinger B, Nevitt MC, Stone KL (Study of Osteoporotic Fractures Research Group). Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann Intern Med. 2001;134:561-568. (Pubitemid 32245317)
260. Muddle AH, Houben AJ, Nieuwenhuijzen Kruseman AC. Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf). 1994;41:421-424. (Pubitemid 24301273)
261. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K. Normalization of serum thyrotropin by mean of radioiodine treatment in subclinical hyperthyroidism: Effect of bone loss in postmenopausal women. Clin Endocrinol (Oxf). 1998;48:285-290. (Pubitemid 28137639)
262. Kumeda Y, Inaba M, Tahara H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2000;85:4157-4161. (Pubitemid 32055367)
263. Tauchmanovà L, Nuzzo V, Del Puente A, et al. Reduced bone mass detected by bone quantitative ultrasonometry and DEXA in pre- and postmenopausal women with endogenous subclinical hyperthyroidism. Maturitas. 2004; 48:299-306. (Pubitemid 38781155)
264. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS. The impact of overt and subclinical hyperthyroidism on skeletal muscle. Thyroid. 2006;16:375-380.
265. Flynn RW, Bonellie SR, Jung RT, MacDonald TM, Morris AD, Leese GP. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186-193.
266. Roberts LM, Pattison H, Roalfe A, et al. Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? Ann Intern Med. 2006; 145:573-581. (Pubitemid 46780936)
267. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frölich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591-2599. (Pubitemid 39577515)
268. Kalmijn S, Mehta KM, Pols HA, Hofman A, Drexhage HA, Breteler MM. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin Endocrinol (Oxf). 2000;53:733-737. (Pubitemid 32096685)
269. Ceresini G, Lauretani F, Maggio M, et al. Thyroid function abnormalities and cognitive impairment in elderly people: Results of the Invecchiare in Chianti study. J Am Geriatr Soc. 2009;57:89-93.
270. Sawin CT, Geller A, Kaplan MM, Bacharach P, Wilson PW, Hershman JM. Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. Arch Intern Med. 1991;151:165-168.
271. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10-year cohort study. Lancet. 2001;358:861-865. (Pubitemid 32900566)
272. Iervasi G, Molinaro S, Landi P, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007;167:1526-1532. (Pubitemid 47124183)
273. Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction and blood pressure: A community-based study. Clin Endocrinol (Oxf). 2006;65:486-491. (Pubitemid 44414272)
274. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B. Subclinical thyroid dysfunction and mortality: An estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. Eur J Endocrinol. 2008;159:329-341.
275. Ochs N, Auer R, Bauer DC, et al. Meta-analysis: Subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008;148:832-845. (Pubitemid 351786932)
276. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228-238. (Pubitemid 38082818)
277. Greenlund LJ, Nair KS, Brennan MD. Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. Endocr Pract. 2008;14: 973-978.
278. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J. Management of Graves' hyperthyroidism in pregnancy: Focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol. 2009;160:1-8.
279. Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med. 1994;331:1072-1078.
280. Glinoer D. The regulation of thyroid function in pregnancy: Pathways of endocrine adaptation from physiology to pathology. Endocr Rev. 1997;18:404-433. (Pubitemid 27246883)
281. Hershman JM. The role of human chorionic gonadotropin as a thyroid stimulator in normal pregnancy. J Clin Endocrinol Metab. 2008;93:3305-3306.
282. Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ. Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: Trends and associations across trimesters in iodine sufficiency. Thyroid. 2004;14:1084-1090. (Pubitemid 40076135)
283. Mandel SJ, Spencer CA, Hollowell JG. Are detection and treatment of thyroid insufficiency in pregnancy feasible? Thyroid. 2005;15:44-53. (Pubitemid 40223500)
284. Weeke J, Dybkjaer L, Granlie K, et al. A longitudinal study of serum TSH, and total and free iodothyronines during normal pregnancy. Acta Endocrinol (Copenh). 1982; 101:531-537. (Pubitemid 13196566)
285. Nelson JC, Wang R, Asher DT, Wilcox RB. The nature of analogue-based free thyroxine estimates. Thyroid. 2004; 14:1030-1036. (Pubitemid 40076127)
286. Lee RH, Spencer CA, Mestman JH, et al. Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol. 2009;200:260.e1-e6.
287. Gong Y, Hoffman BR. Free thyroxine reference interval in each trimester of pregnancy determined with the Roche Modular E-170 electrochemiluminescent immunoassay. Clin Biochem. 2008;41:902-906.
288. Silvio R, Swapp KJ, La'ulu SL, Hansen-Suchy K, Roberts WL. Method specific second-trimester reference intervals for thyroid-stimulating hormone and free thyroxine. Clin Biochem. 2009;42:750-753.
289. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG. Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol. 2006;107:337-341.
290. Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG. Thyrotoxicosis complicating pregnancy. Am J Obstet Gynecol. 1989;160:63-70. (Pubitemid 19055258)
291. Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH. Low birth weight and preeclampsia in pregnancies complicated by hyperthyroidism. Obstet Gynecol. 1994;84:946-949. (Pubitemid 24360253)
292. Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Bio. 1994;54:159-163.
293. Vos XG, Smit N, Endert E, Tijssen JG, Wiersinga WM. Frequency and characteristics of TBII-seronegative patients in a population with untreated Graves' hyperthyroidism: A prospective study. Clin Endocrinol (Oxf). 2008; 69:311-317. (Pubitemid 352009024)
294. Amino N, Tada H, Hidaka Y. Postpartum autoimmune thyroid syndrome: A model of aggravation of autoimmune disease. Thyroid. 1999;9:705-713. (Pubitemid 29357915)
295. Mortimer RH, Tyack SA, Galligan JP, Perry-Keene DA, Tan YM. Graves' disease in pregnancy: TSH receptor binding inhibiting immunoglobulins and maternal and neonatal thyroid function. Clin Endocrinol (Oxf). 1990; 32:141-152. (Pubitemid 20039193)
296. Momotani N, Noh JY, Ishikawa N, Ito K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. J Clin Endocrinol Metab. 1997;82:3633-3636. (Pubitemid 27509348)
297. Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J. Guidelines for TSH-receptor antibody measurements in pregnancy: Results of an evidence-based symposium organized by the European Thyroid Association. Eur J Endocrinol. 1998;139:584-586. (Pubitemid 29030394)
298. Senior B, Chernoff HL. Iodide goiter in the newborn. Pediatrics. 1971;47:510-515.
299. Geelhoed GW. Surgery of the endocrine glands in pregnancy. Clin Obstet Gynecol. 1983;26:865-889. (Pubitemid 14219664)
300. Seeley BL, Burrow GN. Thyrotoxicosis in pregnancy. Endocrinologist. 1991;1:409-417.
301. Chan GW, Mandel SJ. Therapy insight: Management of Graves' disease during pregnancy. Nat Clin Pract Endocrinol Metab. 2007;3:470-478. (Pubitemid 46808738)
302. Zakarija M, McKenzie JM. Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab. 1983;57:1036-1040. (Pubitemid 14204307)
303. Polak M, Le Gac I, Vuillard E, et al. Fetal and neonatal thyroid function in relation to maternal Graves' disease. Best Pract Res Clin Endocrinol Metab. 2004;18:289-302. (Pubitemid 38801670)
304. Roti E, Uberti E. Post-partum thyroiditis-a clinical update. Eur J Endocrinol. 2002;146:275-279.
305. Stagnaro-Green A. Clinical review 152: Postpartum thyroiditis. J Clin Endocrinol Metab. 2002;87:4042-4047.
306. Kuijpens JL, Pop VJ, Vader HL, Drexhage HA, Wiersinga WM. Prediction of post partum thyroid dysfunction: Can it be improved? Eur J Endocrinol. 1998;139: 36-43. (Pubitemid 28351233)
307. Gorman CA. Radioiodine and pregnancy. Thyroid. 1999; 9:721-726. (Pubitemid 29357917)
308. Davanzo R, Rubert L, Oretti C. Meta-variability of advice on drugs in the breastfeeding mother: The example of beta-blockers. Arch Dis Child Fetal Neonatal Ed. 2008;93:F249-F250.
309. Bahn RS. Graves' ophthalmopathy. New Engl J Med. 2010;362:726-738.
310. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: A novel approach. Br J Ophthalmol. 1989;73:639-644. (Pubitemid 19202075)
311. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9-14 (Pubitemid 27313981)
312. Bartalena L, Baldeschi L, Dickinson AJ, et al. Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid. 2008;18:333-346. (Pubitemid 351415802)
313. de Juan E Jr., Hurley DP, Sapira JD. Racial differences in normal values of proptosis. Arch Intern Med. 1980; 140:1230-1231. (Pubitemid 10048820)
314. Sarinnapakorn V, Sridama V, Sunthornthepvarakul T. Proptosis in normal Thai samples and thyroid patients. J Med Assoc Thai. 2007;90:679-683. (Pubitemid 46631812)
315. Tsai CC, Kau HC, Kao SC, Hsu WM. Exophthalmos of patients with GD in Chinese of Taiwan. Eye (Lond). 2006; 20:569-573.
316. Yeatts RP. Quality of life in patients with Graves ophthalmopathy. Trans Am Ophthalmol Soc. 2005;103:368-411.
317. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: The GO-QOL. Br J Ophthalmol. 1998;82: 773-779. (Pubitemid 28376907)
318. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med. 1998;338:73-78. (Pubitemid 28042269)
319. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992; 326:1733-1738.
320. Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab. 2006;91:3464-3470. (Pubitemid 44402120)
321. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol. 1994;130:494-497. (Pubitemid 24165777)
322. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern Med. 1990;150:1098-1101. (Pubitemid 20155338)
323. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab. 2005;90:5321-5323. (Pubitemid 41262294)
324. Sridama V, DeGroot LJ. Treatment of Graves' disease and the course of ophthalmopathy. Am J Med. 1989;87:70-73. (Pubitemid 19179412)
325. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: Impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996;45:477-481. (Pubitemid 26383428)
326. Eisenberg MJ, Filion KB, Yavin D, et al. Pharmacotherapies for smoking cessation: A meta-analysis of randomized controlled trials. CMAJ. 2008;179:135-144. (Pubitemid 352020119)
327. Fiore MC, Jaén CR. A clinical blueprint to accelerate the elimination of tobacco use. JAMA. 2008;299:2083-2085. (Pubitemid 351656590)
328. Lai A, Sassi L, Compri E, et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent graves' orbitopathy: A retrospective cohort study. J Clin Endocrinol Metab. 2010;95:1333-1337.
329. Fernández Sánchez JR, Rosell Pradas J, Carazo Martinez O, et al. Graves' ophthalmopathy after subtotal thyroidectomy and radioiodine therapy. Br J Surg. 1993; 80:1134-1136. (Pubitemid 23284039)
330. Järhult J, Rudberg C, Larsson E, et al. Graves' disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. Thyroid. 2005;15:1157-1164. (Pubitemid 41720722)
331. Domoslawski P, Lukienczuk T, Forkasiewicz Z, et al. Influence of total thyroidectomy on orbital opthalmopathy and levels of antithyroid antibodies in patients with Graves' disease. Polski Przeglad Chirurgiczny. 2007;79:303-312. (Pubitemid 46374304)
332. Vannucchi G, Campi I, Covelli D, et al. Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J Clin Endocrinol Metab. 2009;94:3381-3386.
333. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med. 1995;333:1688-1694. (Pubitemid 126634606)
334. Hintze G, Blombach O, Fink H, Burkhardt U, Kobberling J. Risk of iodine-induced thyrotoxicosis after coronary angiography: An investigation in 788 unselected subjects. Eur J Endocrinol. 1999;140:264-267. (Pubitemid 29155586)
335. Martin FI, Tress BW, Colman PG, Deam DR. Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. Am J Med. 1993;95:78-82. (Pubitemid 23205930)
336. Conn JJ, Sebastian MJ, Deam D, Tam M, Martin FI. A prospective study of the effect of nonionic contrast media on thyroid function. Thyroid. 1996;6:107-110. (Pubitemid 26153007)
337. Roti E, Gardini E, Minelli R, et al. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. J Clin Endocrinol Metab. 1993;76: 928-932. (Pubitemid 23110840)
338. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore). 1983;62:1-20. (Pubitemid 13191820)
339. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E. Clinical review 169: Interferon-alpha-related thyroid disease: Pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89:3656-3661.
340. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13:547-551.
341. Koh LK, Greenspan FS, Yeo PP. Interferon-alpha induced thyroid dysfunction: Three clinical presentations and a review of the literature. Thyroid. 1997;7:891-896. (Pubitemid 28041664)
342. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005;118:706-714. (Pubitemid 40897652)
343. udica-Souza C, Burch HB. Amiodarone-induced thyroid dysfunction. Endocrinologist. 1999;9:216-227. (Pubitemid 29256953)
344. Martino E, Safran M, Aghini-Lombardi F, et al. Enviromental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Int Med. 1984;101:28-34. (Pubitemid 14088063)
345. Eaton SE, Euinton HA, Newman CM, Weetman AP, Bennet WM. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: Role of colour-flow Doppler sonography. Clin Endocrinol (Oxf). 2002; 56:33-38. (Pubitemid 34107319)
346. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: Results of a prospective study. J Clin Endocrinol Metab. 1996;81:2930-2933. (Pubitemid 26323888)
347. Erdogan MF, Gulec S, Tutar E, Baskal N, Erdogan G. A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. Thyroid. 2003;13:205-209. (Pubitemid 36596718)
348. Houghton SG, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS. Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. World J Surg. 2004;28:1083-1087. (Pubitemid 40109855)
349. Williams M, Lo Gerfo P. Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: A review and description of the technique. Thyroid. 2002;12:523-525. (Pubitemid 34721551)
350. Nikolai TF, Coombs GJ, McKenzie AK, Miller RW, Weir GJ, Jr. Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). Arch Intern Med. 1982;142:2281-2283. (Pubitemid 13210251)
351. Sicilia V, Mezitis S. A case of acute suppurative thyroiditis complicated by thyrotoxicosis. J Endocrinol Invest. 2006; 29:997-1000. (Pubitemid 46344234)
352. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610-638. (Pubitemid 26425259)
353. Ross DS. Syndromes of thyrotoxicosis with low radioactive iodine uptake. Endocrinol Metab Clin North Am. 1998;27:169-185. (Pubitemid 28144961)
354. Kung AW, Ma JT, Wang C, Young RT. Hyperthyroidism during pregnancy due to coexistence of struma ovarii and Graves' disease. Postgrad Med J. 1990;66:132-133. (Pubitemid 20120906)
355. Hershman JM. Human chorionic gonadotropin and the thyroid: Hyperemesis gravidarum and trophoblastic tumors. Thyroid. 1999;9:653-657. (Pubitemid 29357906)
356. Goodarzi MO, Van Herle AJ. Thyrotoxicosis in a male patient associated with excess human chorionic gonadotropin production by germ cell tumor. Thyroid. 2000;10: 611-619.
357. Hedberg CW, Fishbein DB, Janssen RS, et al. An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med. 1987; 316:993-998. (Pubitemid 17047922)
358. Kasagi K, Takeuchi R, Miyamoto S, et al. Metastatic thyroid cancer presenting as thyrotoxicosis: Report of three cases. Clin Endocrinol (Oxf). 1994;40:429-434. (Pubitemid 24194640)